Lawson Kroeker Investment Management Inc. NE Cuts Stock Position in Teleflex Incorporated (NYSE:TFX)

Lawson Kroeker Investment Management Inc. NE lessened its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 84.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,850 shares of the medical technology company's stock after selling 15,616 shares during the quarter. Lawson Kroeker Investment Management Inc. NE's holdings in Teleflex were worth $711,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. T. Rowe Price Investment Management Inc. boosted its stake in Teleflex by 2.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 8,633,473 shares of the medical technology company's stock worth $2,155,174,000 after purchasing an additional 181,393 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Teleflex by 1.7% in the first quarter. Vanguard Group Inc. now owns 5,147,062 shares of the medical technology company's stock worth $1,826,333,000 after buying an additional 83,858 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Teleflex by 0.3% during the first quarter. BlackRock Inc. now owns 3,982,749 shares of the medical technology company's stock worth $1,008,870,000 after buying an additional 13,204 shares during the period. Morgan Stanley grew its holdings in shares of Teleflex by 535.8% during the fourth quarter. Morgan Stanley now owns 2,691,192 shares of the medical technology company's stock valued at $671,803,000 after buying an additional 2,267,889 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Teleflex by 2.0% during the first quarter. State Street Corp now owns 2,328,957 shares of the medical technology company's stock valued at $589,948,000 after buying an additional 44,583 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on TFX shares. Truist Financial reduced their target price on Teleflex from $270.00 to $265.00 and set a "hold" rating for the company in a research note on Friday, February 23rd. JMP Securities reaffirmed a "market outperform" rating and set a $285.00 target price on shares of Teleflex in a report on Friday, February 23rd. Raymond James increased their price target on shares of Teleflex from $227.00 to $271.00 and gave the stock an "outperform" rating in a report on Wednesday, December 20th. Royal Bank of Canada decreased their price objective on shares of Teleflex from $272.00 to $265.00 and set an "outperform" rating for the company in a research note on Friday, February 23rd. Finally, StockNews.com downgraded shares of Teleflex from a "buy" rating to a "hold" rating in a report on Friday, February 23rd. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Teleflex has an average rating of "Moderate Buy" and an average target price of $265.56.

Teleflex Stock Performance

Shares of NYSE TFX traded down $0.70 during midday trading on Thursday, reaching $217.54. 178,015 shares of the stock were exchanged, compared to its average volume of 260,982. The company has a quick ratio of 1.29, a current ratio of 2.32 and a debt-to-equity ratio of 0.39. The firm has a market cap of $10.25 billion, a price-to-earnings ratio of 28.95, a PEG ratio of 2.08 and a beta of 1.11. The firm has a 50-day simple moving average of $230.87 and a two-hundred day simple moving average of $224.74. Teleflex Incorporated has a twelve month low of $177.63 and a twelve month high of $276.43.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, beating the consensus estimate of $3.26 by $0.12. The company had revenue of $773.90 million for the quarter, compared to analyst estimates of $769.01 million. Teleflex had a net margin of 11.98% and a return on equity of 14.98%. The firm's revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business earned $3.52 earnings per share. As a group, analysts anticipate that Teleflex Incorporated will post 13.73 EPS for the current fiscal year.

Teleflex Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.36 dividend on an annualized basis and a yield of 0.63%. Teleflex's dividend payout ratio is currently 18.06%.

Insider Buying and Selling at Teleflex

In other news, VP Cameron P. Hicks sold 7,401 shares of the company's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the transaction, the vice president now directly owns 10,050 shares of the company's stock, valued at approximately $2,261,250. The sale was disclosed in a filing with the SEC, which is available at this link. 1.41% of the stock is owned by corporate insiders.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.